KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 151 filers reported holding KEROS THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.06 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $9,077,254 | -23.1% | 198,627 | +11.4% | 1.22% | -16.1% |
| Q1 2024 | $11,805,777 | -17.6% | 178,335 | -50.5% | 1.45% | -28.2% |
| Q4 2023 | $14,332,168 | +50.6% | 360,467 | +20.8% | 2.02% | +15.8% |
| Q3 2023 | $9,515,383 | -14.4% | 298,475 | +7.8% | 1.74% | -9.5% |
| Q2 2023 | $11,122,427 | +45.3% | 276,815 | +54.4% | 1.93% | +15.8% |
| Q1 2023 | $7,655,683 | +25.7% | 179,290 | +41.4% | 1.66% | +2.7% |
| Q4 2022 | $6,088,456 | +62.0% | 126,790 | +26.9% | 1.62% | +51.6% |
| Q3 2022 | $3,759,000 | +184.8% | 99,927 | +109.1% | 1.07% | +120.0% |
| Q2 2022 | $1,320,000 | -66.6% | 47,788 | -34.3% | 0.49% | -58.0% |
| Q1 2022 | $3,953,000 | -3.3% | 72,690 | +4.0% | 1.16% | +28.3% |
| Q4 2021 | $4,088,000 | – | 69,861 | – | 0.90% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 276,000 | $7,626,000 | 3.44% |
| First Light Asset Management, LLC | 598,333 | $16,532,000 | 1.92% |
| Fairmount Funds Management LLC | 272,498 | $7,529,000 | 1.72% |
| Deep Track Capital, LP | 739,528 | $20,433,000 | 1.34% |
| Nantahala Capital Management | 911,901 | $25,196,000 | 1.26% |
| Octagon Capital Advisors LP | 152,249 | $4,207,000 | 1.12% |
| CHI Advisors LLC | 103,429 | $2,858,000 | 1.09% |
| Altium Capital Management LP | 88,000 | $2,431,000 | 0.97% |
| Orbimed Advisors | 1,679,417 | $46,402,000 | 0.84% |
| Parkman Healthcare Partners LLC | 47,788 | $1,320,000 | 0.49% |